These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 32665252)
1. Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window. Gillis A; Sreenivasan V; Christie MJ Mol Pharmacol; 2020 Oct; 98(4):410-424. PubMed ID: 32665252 [TBL] [Abstract][Full Text] [Related]
2. G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists. Stahl EL; Schmid CL; Acevedo-Canabal A; Read C; Grim TW; Kennedy NM; Bannister TD; Bohn LM Proc Natl Acad Sci U S A; 2021 Nov; 118(48):. PubMed ID: 34819362 [TBL] [Abstract][Full Text] [Related]
3. Biased versus Partial Agonism in the Search for Safer Opioid Analgesics. Azevedo Neto J; Costanzini A; De Giorgio R; Lambert DG; Ruzza C; Calò G Molecules; 2020 Aug; 25(17):. PubMed ID: 32854452 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological, and structural explorations of a series of μ-opioid receptor (MOR) agonists with high G protein signaling bias. Yang Y; Wang Y; Zuo A; Li C; Wang W; Jiang W; Zhang X; Che X; Zhang Y; Wu W; Cen X; Wang H; Tian J Eur J Med Chem; 2022 Jan; 228():113986. PubMed ID: 34802839 [TBL] [Abstract][Full Text] [Related]
6. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Gillis A; Gondin AB; Kliewer A; Sanchez J; Lim HD; Alamein C; Manandhar P; Santiago M; Fritzwanker S; Schmiedel F; Katte TA; Reekie T; Grimsey NL; Kassiou M; Kellam B; Krasel C; Halls ML; Connor M; Lane JR; Schulz S; Christie MJ; Canals M Sci Signal; 2020 Mar; 13(625):. PubMed ID: 32234959 [TBL] [Abstract][Full Text] [Related]
7. Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists. Stahl EL; Bohn LM Biochemistry; 2022 Sep; 61(18):1923-1935. PubMed ID: 34468132 [TBL] [Abstract][Full Text] [Related]
8. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Vasudevan L; Vandeputte M; Deventer M; Wouters E; Cannaert A; Stove CP Biochem Pharmacol; 2020 Jul; 177():113910. PubMed ID: 32179045 [TBL] [Abstract][Full Text] [Related]
9. Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of β-arrestin/G protein signaling bias. Pineyro G; Nagi K Cell Signal; 2021 Apr; 80():109906. PubMed ID: 33383156 [TBL] [Abstract][Full Text] [Related]
10. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. DeWire SM; Yamashita DS; Rominger DH; Liu G; Cowan CL; Graczyk TM; Chen XT; Pitis PM; Gotchev D; Yuan C; Koblish M; Lark MW; Violin JD J Pharmacol Exp Ther; 2013 Mar; 344(3):708-17. PubMed ID: 23300227 [TBL] [Abstract][Full Text] [Related]
11. In Vitro Effects of Ligand Bias on Primate Mu Opioid Receptor Downstream Signaling. Zhang X; Hutchins SD; Blough BE; Vallender EJ Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32503269 [TBL] [Abstract][Full Text] [Related]
12. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias. Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391 [TBL] [Abstract][Full Text] [Related]
13. Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor. Gillis A; Kliewer A; Kelly E; Henderson G; Christie MJ; Schulz S; Canals M Trends Pharmacol Sci; 2020 Dec; 41(12):947-959. PubMed ID: 33097283 [TBL] [Abstract][Full Text] [Related]
14. Opioid signaling and design of analgesics. Paul B; Sribhashyam S; Majumdar S Prog Mol Biol Transl Sci; 2023; 195():153-176. PubMed ID: 36707153 [TBL] [Abstract][Full Text] [Related]
15. Biased Agonism: Lessons from Studies of Opioid Receptor Agonists. Kelly E; Conibear A; Henderson G Annu Rev Pharmacol Toxicol; 2023 Jan; 63():491-515. PubMed ID: 36170657 [TBL] [Abstract][Full Text] [Related]
16. Mu-Opioid receptor biased ligands: A safer and painless discovery of analgesics? Madariaga-Mazón A; Marmolejo-Valencia AF; Li Y; Toll L; Houghten RA; Martinez-Mayorga K Drug Discov Today; 2017 Nov; 22(11):1719-1729. PubMed ID: 28743488 [TBL] [Abstract][Full Text] [Related]
17. Carfentanil is a β-arrestin-biased agonist at the μ opioid receptor. Ramos-Gonzalez N; Groom S; Sutcliffe KJ; Bancroft S; Bailey CP; Sessions RB; Henderson G; Kelly E Br J Pharmacol; 2023 Sep; 180(18):2341-2360. PubMed ID: 37005796 [TBL] [Abstract][Full Text] [Related]
18. A Biased View of Conibear AE; Kelly E Mol Pharmacol; 2019 Nov; 96(5):542-549. PubMed ID: 31175184 [TBL] [Abstract][Full Text] [Related]
19. Usefulness for the combination of G-protein- and β-arrestin-biased ligands of μ-opioid receptors: Prevention of antinociceptive tolerance. Mori T; Kuzumaki N; Arima T; Narita M; Tateishi R; Kondo T; Hamada Y; Kuwata H; Kawata M; Yamazaki M; Sugita K; Matsuzawa A; Baba K; Yamauchi T; Higashiyama K; Nonaka M; Miyano K; Uezono Y; Narita M Mol Pain; 2017; 13():1744806917740030. PubMed ID: 29056067 [TBL] [Abstract][Full Text] [Related]